HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stephen T Keir Selected Research

KM-233

11/2012Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stephen T Keir Research Topics

Disease

96Neoplasms (Cancer)
01/2019 - 01/2005
22Glioma (Gliomas)
01/2022 - 05/2003
21Glioblastoma (Glioblastoma Multiforme)
01/2022 - 01/2005
13Brain Neoplasms (Brain Tumor)
01/2019 - 05/2003
13Neuroblastoma
01/2017 - 05/2008
13Leukemia
02/2015 - 06/2008
11Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2017 - 01/2008
9Ewing Sarcoma (Sarcoma, Ewing)
02/2015 - 06/2008
9Rhabdomyosarcoma
09/2012 - 11/2005
7Osteosarcoma (Osteogenic Sarcoma)
12/2012 - 06/2008
5Sarcoma (Soft Tissue Sarcoma)
09/2012 - 04/2008
4Medulloblastoma
09/2017 - 01/2010
4Hypoxia (Hypoxemia)
01/2016 - 02/2010
4Wilms Tumor (Wilm's Tumor)
08/2012 - 05/2008
4Rhabdoid Tumor (Rhabdoid Tumors)
12/2009 - 05/2008
2Neoplasm Metastasis (Metastasis)
01/2019 - 02/2010
2Melanoma (Melanoma, Malignant)
01/2019 - 07/2011
2Breast Neoplasms (Breast Cancer)
01/2019 - 10/2009
2Astrocytoma (Pilocytic Astrocytoma)
11/2018 - 10/2010
2Ependymoma
01/2018 - 11/2005
2Weight Loss (Weight Reduction)
07/2007 - 09/2006
2Central Nervous System Neoplasms
07/2007 - 05/2003
1Starvation
01/2019
1Poliomyelitis (Polio)
12/2017

Drug/Important Bio-Agent (IBA)

36N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)IBA
01/2017 - 12/2007
10Temozolomide (Temodar)FDA LinkGeneric
01/2022 - 05/2003
8Pharmaceutical PreparationsIBA
01/2018 - 09/2007
7Phosphotransferases (Kinase)IBA
12/2015 - 01/2005
7Proteins (Proteins, Gene)FDA Link
12/2014 - 06/2007
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2017 - 09/2006
5ErbB Receptors (EGF Receptor)IBA
12/2015 - 01/2005
5Sirolimus (Rapamycin)FDA Link
05/2012 - 09/2007
4Antineoplastic Agents (Antineoplastics)IBA
10/2016 - 07/2008
4Immunotoxins (Immunotoxin)IBA
09/2013 - 07/2011
3Bevacizumab (Avastin)FDA Link
11/2018 - 12/2010
3epidermal growth factor receptor VIIIIBA
07/2018 - 09/2013
3MicroRNAs (MicroRNA)IBA
01/2016 - 01/2011
3Tyrosine (L-Tyrosine)FDA Link
12/2015 - 06/2007
3Angiogenesis InhibitorsIBA
11/2014 - 12/2010
3Topotecan (Hycamtin)FDA LinkGeneric
11/2013 - 05/2010
3Vincristine (Oncovin)FDA LinkGeneric
08/2013 - 12/2007
3LigandsIBA
11/2012 - 07/2010
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
12/2010 - 11/2005
2ABT-737IBA
01/2019 - 06/2008
2EnzymesIBA
01/2019 - 02/2015
2purineIBA
01/2019 - 03/2016
2navitoclaxIBA
01/2019 - 06/2008
2A-factor (Streptomyces)IBA
01/2019 - 01/2011
2Sorafenib (BAY 43-9006)FDA Link
11/2018 - 12/2010
2Irinotecan (Camptosar)FDA LinkGeneric
11/2018 - 05/2003
2Single-Chain AntibodiesIBA
01/2018 - 07/2011
2Focal Adhesion Protein-Tyrosine KinasesIBA
01/2017 - 06/2007
2AntibodiesIBA
01/2016 - 05/2012
2ProdrugsIBA
06/2015 - 09/2011
2talazoparibIBA
02/2015 - 01/2015
2Messenger RNA (mRNA)IBA
12/2014 - 02/2012
2Mitogen-Activated Protein KinasesIBA
12/2014 - 09/2007
2Biological ProductsIBA
12/2014 - 08/2010
2Proteasome InhibitorsIBA
12/2013 - 01/2008
2Bortezomib (Velcade)FDA Link
12/2013 - 01/2008
2DNA (Deoxyribonucleic Acid)IBA
05/2013 - 09/2010
2cixutumumabIBA
05/2012 - 07/2010
2Mechanistic Target of Rapamycin Complex 1IBA
05/2012 - 02/2012
2cediranib (AZD2171)IBA
04/2012 - 03/2008
2Cytotoxins (Cytolysins)IBA
04/2012 - 01/2010
2Cisplatin (Platino)FDA LinkGeneric
04/2012 - 05/2008
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
04/2012 - 12/2007
2MLN 8237IBA
11/2011 - 07/2010
2Growth Factor ReceptorsIBA
07/2010 - 01/2005
2Tyrosine Kinase InhibitorsIBA
10/2009 - 11/2005
2laromustine (VNP40101M)IBA
09/2008 - 07/2007
2EverolimusFDA Link
09/2007 - 01/2005
2Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
11/2005 - 01/2005
1Gentian Violet (Violet, Crystal)FDA Link
01/2022
11-phenyl-3,3-dimethyltriazene (PDT)IBA
01/2022
1alpha-2'-deoxythioguanosineIBA
12/2021
1NucleosidesIBA
12/2021
1chondroitin sulfate proteoglycan 4IBA
01/2019
1S63845IBA
01/2019
15'-methylthioadenosine phosphorylase (methylthioadenosine nucleosidase)IBA
01/2019
1venetoclaxIBA
01/2019
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
11/2018
1VemurafenibIBA
11/2018
1cobimetinibIBA
11/2018
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
11/2018
1futuximabIBA
07/2018
1ChromatinIBA
01/2018
1Small Interfering RNA (siRNA)IBA
01/2018
1poliovirus receptorIBA
12/2017
1Formaldehyde (Formol)FDA Link
12/2017
1ParaffinIBA
12/2017
1Biomarkers (Surrogate Marker)IBA
09/2017
1PND 1186IBA
01/2017
1CBLC137IBA
01/2017
1Exportin 1 ProteinIBA
02/2016
1selinexorIBA
02/2016

Therapy/Procedure

23Therapeutics
01/2019 - 01/2005
5Drug Therapy (Chemotherapy)
01/2018 - 09/2010
3Immunotherapy
12/2017 - 07/2011
2Withholding Treatment
07/2008 - 06/2008